Research Classification
Research Interests
Relevant Thesis-Based Degree Programs
Affiliations to Research Centres, Institutes & Clusters
Research Options
Research Methodology
Recruitment
Sex differences at the genetic/epigenetic level in early development.
Developmental origin of extraenbryonic tissues and their epigenetic programming
Congenital Heart Defects and confined placental mosaicism
I generally only accept graduate students through the Medical Genetics or GSAT rotation programs. Strong background in genetics and stats/bioinformatics preferred. Integrity, honesty, passion, ability to work independently and in teams, and critical thinking are key skills needed.
Complete these steps before you reach out to a faculty member!
Check requirements
- Familiarize yourself with program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit the graduate degree program listing and program-specific websites.
- Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study. This is either indicated in the program profile under "Admission Information & Requirements" - "Prepare Application" - "Supervision" or on the program website.
Focus your search
- Identify specific faculty members who are conducting research in your specific area of interest.
- Establish that your research interests align with the faculty member’s research interests.
- Read up on the faculty members in the program and the research being conducted in the department.
- Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
Make a good impression
- Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
- Do not send non-specific, mass emails to everyone in the department hoping for a match.
- Address the faculty members by name. Your contact should be genuine rather than generic.
- Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department. The supervision enquiry form guides you with targeted questions. Ensure to craft compelling answers to these questions.
- Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to pique someone’s interest.
- Demonstrate that you are familiar with their research:
- Convey the specific ways you are a good fit for the program.
- Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting.
- Be enthusiastic, but don’t overdo it.
Attend an information session
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
ADVICE AND INSIGHTS FROM UBC FACULTY ON REACHING OUT TO SUPERVISORS
These videos contain some general advice from faculty across UBC on finding and reaching out to a potential thesis supervisor.
Graduate Student Supervision
Doctoral Student Supervision
Dissertations completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest dissertations.
The full abstract for this thesis is available in the body of the thesis, and will be available when the embargo expires.
View record
DNA methylation (DNAm) is an epigenetic mark that can control or reflect gene expression in a highly cell-specific manner. Placental DNAm has been studied in various contexts, however, several sources of variation remain uncharacterized. Before we are able to understand how placental DNAm contributes to important health-relevant contexts, we must develop an understanding of the underlying normal variation that occurs in the placental methylome. For example, a high proportion of variation in DNAm can vary by ethnicity and genotype. DNAm is also highly cell-specific, and the placenta is a heterogeneous tissue comprised of several distinct cell populations. However, due to difficulty of isolating cell populations, most placental DNAm research is conducted on whole placental chorionic villi tissue. Isolating placental tissue without contamination from maternal tissue, such as decidua and blood, can be challenging, especially in earlier gestation samples where sampling enough tissue is difficult.In this thesis, I hypothesize that a large proportion of the variation in placental DNAm can attributed to ethnicity, genetic ancestry, cell composition, cell-specific effects, and the presence of maternal cells. Using high-density DNAm microarray profiling, and open access genomic data repositories, I assessed these factors in placental samples with various phenotypes. I found that ethnicity and genetic ancestry are associated with placental DNAm variation in samples containing self-reports of White/Caucasian, East Asian/Asian, and Black/African American ethnicity. Further, I found that it is possible to predict ethnicity and genetic ancestry with high accuracy and reliability from placental DNAm. Another major source of variation is cell-specific DNAm, which I characterized from placental samples of first trimester and term pregnancies. I found that trophoblast and Hofbauer cells are highly epigenetically distinct, and many placental epigenetic features are conserved in trophoblasts but not always in other placental cells. I developed a reference to estimate cell composition from placental chorionic villi DNAm. Lastly, I developed an approach to estimate maternal cells present in chorionic villi samples, using DNAm, and found several previously published placental DNAm studies to contain maternally-contaminated samples. Overall, I contributed to our understanding of placental DNAm, and have provided bioinformatic tools for future placental DNAm research.
View record
Fetal growth restriction (FGR) is a common pregnancy complication in which the fetus does not grow to its genetic potential due to a pathological cause, which puts it at greater risk for morbidity and mortality in the perinatal period and poor health outcomes in childhood and adulthood. Although the etiology of FGR is diverse, insufficient function of the placenta underlies many cases, as the placenta is a crucial organ to support fetal growth and development and a healthy pregnancy. One of the few established genetic contributors to placental insufficiency and non-syndromic FGR is trisomy confined to the placenta. Beyond this, the contribution of smaller genomic imbalances (copy number variants) or common single nucleotide variants and their impact on gene regulation in the placenta, for example through DNA methylation, remains largely unexplored.In this thesis, I hypothesized that placental genomic imbalances, including aneuploidy and copy number variants (CNVs), and candidate single nucleotide variants in a gene relevant to DNA methylation (DNAme) are associated with poor fetal growth and/or altered placental DNAme. Using molecular-cytogenetic and microarray techniques, I assessed aneuploidy and CNVs in placentas from infants born small-for-gestational age (SGA) and adequately-grown controls. I found that confined placental mosaicism of autosomal aneuploidies or rare candidate CNVs involving genes related to placental function or growth were present in about 18% of SGA cases, and that CNV load was not associated with SGA. I also characterized a novel case of eight 2-4 Mb duplications confined to the placenta of an infant with FGR, in which the CNVs arose de novo in a cell in the trophoblast lineage. Finally, I studied two candidate single nucleotide polymorphisms in MTHFR, involved in the metabolic pathway that produces one-carbon units for methylation reactions and purine synthesis. I found that these variants were not associated with altered placental DNAme, and that there was only a trend for increased risk of placental insufficiency complications of FGR and/or preeclampsia. Through these studies, I contributed to our understanding of genetic variation in the placenta and its association with FGR and placental insufficiency, and provided a foundation from which future studies can build.
View record
Acute chorioamnionitis (aCA), a preterm birth (PTB) associated inflammatory condition, can have adverse effects on the health of the baby. This condition is characterized by inflammatory lesions in the fetal membranes and can also involve the chorionic plate in the placenta. Histologic examination of the placenta is the gold standard for diagnosing aCA, but is only possible after delivery; thus, this method is not suitable for prenatal diagnosis of aCA. This necessitates the development of non-invasive biomarkers to allow effective management of the disease and hence, reduce the incidence of PTB. Additionally, genetic variation in immune-system genes may contribute to the placenta’s inflammatory responses, thus influencing susceptibility to aCA. The overarching objective of this dissertation is to understand how genetic, epigenetic, and miRNA variation in the placenta is associated with the disruption of immune balance in aCA. To achieve this, I first examined the association of single nucleotide polymorphisms (SNPs) in innate immune system genes and aCA status. I observed that differences in IL6 (rs1800796) placental allele frequencies were associated with the presence of aCA. Further, I showed the IL6 SNP may regulate IL6 gene expression and DNA methylation (DNAme) in the placenta, and alter disease risk to aCA. Secondly, using the Illumina HumanMethylation850 BeadChip, I characterized epigenetic variation associated with aCA in placenta and fetal membranes. Specifically, I observed that aCA-affected placentas showed a unique DNAme profile that may reflect an increase in immune cell number as a response to inflammation and/or represent activation of the innate immune response in the placenta. Lastly, I investigated whether altered miRNA profiles were associated with aCA-affected placentas. Expression was quantified for six inflammation-related miRNAs using quantitative real-time PCR. I observed that expression of miR-518b and miR-338-3p were differentially expressed in aCA-affected placentas. I also showed that miR-518b expression in placenta was associated with IL6 (rs1800796) genotype, where carriers of the C allele exhibited decreased miR-518b expression compared to the carriers of the G allele. In summary, this research uniquely investigated genetic alterations, DNAme, and miRNA expression patterns in aCA-affected placentas, adding insights into the processes likely impacting immune function during aCA.
View record
Preeclampsia (PE), characterized by maternal hypertension and proteinuria, is the leading cause of maternal and perinatal morbidity and mortality worldwide. PE can be subdivided into early-onset PE (EOPE), diagnosis 34 weeks, and late-onset PE (LOPE), diagnosis ≤34 weeks. Intrauterine growth restriction (IUGR), pathologically poor fetal growth, often co-occurs with PE. Both conditions are thought to be due to the placenta, the organ responsible for oxygen and nutrient transport to the fetus, not functioning adequately; this is referred to as placental insufficiency (PI). Currently there is no consistent clinical test to predict pregnancies at risk of these conditions.This dissertation investigated placental genetic and epigenetic profiles to assess their utility to identify novel protein biomarkers in maternal blood and to subclassify PE and IUGR placentas. DNA methylation (DNAm) in the placenta at delivery correlated to second trimester Inhibin alpha and third trimester fibronectin levels in maternal blood, indicating that DNAm alterations may be useful to identify novel biomarkers. Widespread DNAm alterations were identified in EOPE placentas, many of which validated in an independent cohort. These changes can be used to refine clinical diagnoses. Placental DNAm signatures can help to refine clinical diagnoses to create more homogenous pathological groups, aiding in more robust predictive algorithms for PI conditions.Telomere length (TL) was also assessed as a potential biomarker, as it has been reported altered in placentas of PE and IUGR pregnancies. This is thought to be due to the hypoxic environmentiiiassociated with PI which results in DNA damage, and shortened TL. However, correcting for placental gestational age and fetal sex, TL was not shorter in LOPE or IUGR in our population. EOPE placentas trended towards shorter TL (p=0.1). Overall, these studies found that TL is not likely to be an informative marker of PI. These studies show the potential utility of DNAm in identifying novel protein biomarkers in maternal blood, refining clinical diagnoses to create more homogenous subtypes of PI, or as a potential biomarker itself for identifying pregnancies at risk of PI conditions.
View record
High-throughput methods have resulted in a large volume of studies measuring genome-wide DNA methylation (DNAm) in association with human health and disease. Understanding of DNAm patterns may be translated, for example, into predicting children at risk for illness or identifying etiological subtypes within a heterogeneous disease. Addressing biological and technical factors affecting measurement of genome-wide DNAm is essential to reduce false discovery in such studies. This dissertation develops principles for analyzing genome-wide DNAm, with the aim of improving collection and analysis of human developmental data. To this end, I present four studies employing several techniques to measure genome-wide DNAm: DNAm of L1 and Alu repetitive elements in addition to Illumina 27k and 450k DNAm microarrays. In the first of these studies, I found that tissue type, gestational age, technical platform and CpG density contribute to variable measurement of genome-wide DNAm. Subsequent studies primarily used the 450k array to measure genome-wide DNAm, a technology targeting 485,577 sites in the genome. A detailed annotation of the 450k array was created and tested, to enhance this platform’s utility. Array probes targeting sites containing SNPs (4.3%) and non-specific probes (8.6%) were identified, and I examined how these compromised probes may result in spurious discoveries. A pilot study in placental tissue identified batch effects in 450k data. A computational tool was applied to reduce the batch signal, but I demonstrated that when applied to a problematic study design, false biological signal may be introduced. The workflow for processing and analyzing genome-wide DNAm data was finally applied to profile five tissues ascertained from second trimester neural tube defect (NTD)-affect pregnancies. Despite research, medical interventions and public health changes, NTDs remain the second most common congenital abnormality in many parts of the world, and the etiology of these cases is unknown. Using the 450k array, I found 3,342 differentially methylated sites in the kidneys of spina bifida cases compared to gestational-age matched controls, but little alteration in genome-wide DNAm in other NTD tissues. This dissertation contributes methodologies and analytical tools that will help manage bias, improve reproducibility and reduce false discoveries in studies of genome-wide DNAm.
View record
Recurrent miscarriage (RM), defined as 3 or more consecutive spontaneous losses of pregnancy before 20 weeks gestation, affects 1-2% of couples and has a complex etiology. Half of miscarriages from RM cases are caused by chromosomal abnormalities in the embryo and while there are several associated maternal factors, underlying causes and clinically relevant biomarkers have been elusive. I hypothesized that genetic and/or epigenetic factors associated with maternal meiotic non-disjunction, reproductive aging and endocrinological profile, or placental functioning will contribute to the etiology of RM. In these case-control studies, I investigated the association between RM and 1) maternal mutations in synaptonemal complex protein 3 (SYCP3), 2) maternal telomere lengths, 3) maternal polymorphisms in genes in the hypothalamus-pituitary-ovarian (HPO) axis and 4) placental DNA methylation patterns. The findings suggest that maternal mutations in SYCP3 and polymorphisms in HPO axis genes may not contribute significantly to risk for RM. No mutations in SYCP3 were identified in women with RM with at least one trisomic conception. While associations between polymorphisms within the estrogen receptor β, activin receptor 1, prolactin receptor and glucocorticoid receptor genes and RM were identified, these were not significant after correction for multiple comparisons. Aspects of chromosomal biology may be important factors in the etiology of RM. Women with RM had significantly shorter telomeres compared to controls, suggesting altered rates of biological aging. In the placental villi of RM samples, there were few differences in DNA methylation at targeted sites when compared to isolated miscarriages and elective terminations. However, gene ontology analysis showed that imprinted genes and immune response pathways were overrepresented among those sites differentially methylated between RM and elective termination placentas. The RM group additionally had an increase in the number of outlier cases at a select number of imprinted loci. Furthermore, several placental samples from both cases and controls showed aberrant DNA methylation profiles at many loci investigated, suggesting these samples may have global dysregulation of DNA methylation and/or differences in placental composition/functioning. These studies have improved our understanding of mechanisms involved in RM and will contribute to the direction of future research.
View record
Dysregulation of placental and fetal epigenetics can affect gene expression patterns, including the parent-of-origin dependent expression in imprinted genes. While defects of imprinted genes have been implicated in some adverse pregnancy outcomes, little is currently known about the role of epigenetics in regulating normal or pathological human pregnancy and development. The objective of this thesis is to provide fundamental DNA methylation profiles of human fetal and placental development so as to offer insights into the etiology of human disease and adverse pregnancy outcomes. Taking advantage of the unbalanced parental genomic constitutions in triploidies, 45 novel imprinted genes were identified by comparing the genome-wide DNA methylation profiles between 10 diandries and 10 digynies. A comparison of DNA methylation profiles between placentas of different gestations and other somatic tissues showed tissue-specific and gestational age-specific DNA methylation changes in many imprinted genes. To gain insight into the genomic pattern of tissue-specific methylation, DNA methylation profile was evaluated in 5 somatic tissues (brain, kidney, lung, muscle and skin) from eight normal second-trimester fetuses. Tissue-specific differentially methylated regions (tDMRs) were identified in 195 loci, suggesting that tissue-specific methylation is established early in the second trimester. Importantly, only 17% of the identified fetal tDMRs were found to maintain this same tissue-specific methylation in adult tissues, implicating an extensive epigenetic reprogramming between fetus and adult. Besides intra-individual differences, there is also substantial DNA methylation variation between individuals. While many sites show a continuous pattern of DNA methylation variation between different placentas, WNT2, TUSC3 and EPHB4 were identified to have epipolymorphisms at their promoter region. The methylation status at the TUSC3 promoter showed an association with preeclampsia, suggesting a role of DNA methylation change in adverse pregnancy outcomes. A further investigation of DNA methylation profiles in 26 placentas from preeclampsia, IUGR and control subjects showed 34 loci were hypomethylated in the early-onset preeclamptic placentas, with TIMP3 having a potential of being a biomarker for the disorder. These results provided comprehensive DNA methylation profiles for both normal and abnormal fetal and placental tissues, which contribute to the biological and clinical aspects of the pathogenesis of fetal and placental disorders.
View record
Master's Student Supervision
Theses completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest theses.
The Placentomics project aims to create a compendium of various ‘omics tools applied to the study of the human placenta. One of these ‘omics tools is methylomics data collected through the Illumina 850K (EPIC) array. However, there is lack of standardization of the statistical processing of the array data. In this thesis, I studied the technical, clinical, and biological factors that can influence DNAme differences and used these factors to create a standardized processing pipeline. I used 204 samples from three cohorts of pregnant women: 36 samples from a normative cohort (V-NORM), 64 from a SSRI exposed cohort (V-SSRI) and 105 samples from an acute stressor exposed cohort (QF2011). In chapter 2, I evaluated factors that contribute to DNA methylation variability and identified clinical gestational age, PlaNET derived cell type proportions and PlaNET derived genetic ancestry probabilities as important to include in the pipeline, in addition to other R DNAme analysis packages such as minfi and wateRmelon. I then used this pipeline to assess association between DNAme and two biological variables of interest: birth weight (sd) and placental efficiency (placental weight: fetal weight ratio). Three differentially methylated probes met significance (FDR0.05) and strength cut-offs (delta beta >0.05 or delta beta -0.05) in the placental efficiency model only . I further assessed these variables of interest in models that excluded cell type proportions or considered sex stratification. I found no probes that met both cut-offs in these models. In Chapter 3, I developed and standardized a set of metrics to select a normalization method for DNAme arrays. I evaluated 4 within-sample, 2 between-sample, and 1 method that had elements of both (between and within-sample) methods using these metrics. I also evaluated 3 combinations of methods (i.e., Noob and another method). I found a combination of between and within-sample methods (Dasen+Noob) to perform the best on these metrics in this data set. I also found that including Noob prior to another normalization method produced consistently good results on my metrics. Thus, through these studies, I provided a set of standardized tools for the analysis of DNAme data in the placenta.
View record
Major depressive disorder (MDD) is a leading cause of morbidity and disability worldwide, with approximately twice as many women reported to have a lifetime occurrence of MDD than men. MDD is a polygenic trait, wherein hundreds to thousands of common genetic variants with small effect sizes contribute to risk of disease. This study investigated sex differences in the risk factor comorbidity and genetic architecture of MDD in over 16,000 people aged 45-85 from the Canadian Longitudinal Study on Aging (CLSA), with 21% of females (n=1,741) and 12% of males (n=1,055) coded with MDD. Polygenic risk scores (PRS) for individuals were made using sex-stratified and non-sex-specific (“both-sexes”) UK Biobank genome-wide association study summary statistics data. The female sex-specific PRS had higher associations with MDD in females in the top decile of PRS risk (OR = 1.68 (1.32-2.14), p = 2.8E-05) than the male-specific PRS in males (OR = 1.43 (1.07-1.93), p = 0.017) and the both-sexes PRS applied to both sexes (OR = 1.51 (1.25-1.83), p = 2.5E-05). Odds of MDD for the sex-specific PRSs, socioeconomic, lifestyle and clinical risk factors were assessed using a multivariable logistic regression model for each sex. Sex-specific risk factor associations with odds of MDD were found in females (hypothyroidism (OR = 1.42 (1.25-1.63), p = 1.74E-07), not being partnered (OR = 1.34 (1.17-1.52), p = 1.26E-05), having diabetes (OR = 1.30 (1.11-1.52), p = 1.03E-03), higher sex-specific autosomal PRS (OR = 1.10 (1.04-1.16), p = 6.15E-04) and a history of ischemic heart disease (OR = 1.52 (1.14-2.01), p = 3.39E-03)) and males (high blood pressure, OR = 1.35 (1.04-1.47), p = 4.55E-05). Significant differences were observed in the proportion of variables that contributed to the most to each model, evaluated by relative pseudo-R2 values. Age contributed the most to the model for both sexes (73% for females, 57% for males), wherein younger age was associated with higher odds of MDD. The results of this thesis underscore the relevance for sex-disaggregating analyses of complex traits, like MDD, and the incorporation of clinical variables into models of MDD, in applications such as early detection and primary prevention.
View record
Neonates have a uniquely structured immune system characterized by immunotolerance, an unprimed adaptive immune system, and a heavy reliance on innate immune responses. Although this prevents excessive hyperinflammatory responses during gestation and postnatal microbial colonization of the neonate, it also confers vulnerability to infection. This risk is heightened in those born preterm (prior to 37 weeks gestation), as development of their immune system is interrupted by early birth.Throughout gestation, the predominant hematopoietic organ shifts in a defined temporal pattern. Each hematopoietic source produces different types of immune cells in different proportions, to accommodate the needs of the developing fetus. One of the greatest differences between these organs is the release of nucleated red blood cells (nRBCs) into circulation – ranging from the yolk sac, which exclusively releases primitive nRBCs, to the bone marrow, in which erythroid cells are enucleated before entering circulation. Although generally regarded as a consequence of high erythropoietic demand in the fetus, recent functional studies have indicated an immunosuppressive role for fetal nRBCs as well.DNA methylation (DNAm) is the addition of a methyl group to a cytosine base, a modification which does not change the underlying genetic sequence. DNAm mediates hematopoietic lineage commitment and can be a useful marker for cell composition and immune function in blood. Using the Illumina Infinium HumanMethylation450 BeadChip microarray, this thesis establishes DNAm profiles for major cord blood hematopoietic cells in both term and preterm births. In-depth examination of DNAm in term nRBCs revealed that epigenetic marks in this enigmatic cell population are likely highly regulated. Comparisons between cord blood hematopoietic cells collected from term versus preterm births allowed for the identification of both cell-specific and systemic prematurity-associated differential methylation. These findings contribute to current understanding of the molecular mechanisms behind preterm birth and highlight candidate genes for follow-up gene expression or functional analysis of preterm hematopoietic cell populations, including CDC42EP1, CLIP2, FBXO31, the oncogene WWTR1, and tumour suppressor genes STK10 and RARRES3.
View record
Preeclampsia is a leading cause of maternal and fetal death throughout the world. It is caused by placental dysfunction and clinically characterized by hypertension and other adverse outcomes. Early-onset preeclampsia (EOPET) is a severe form of the disorder. Despite much investigation, the underlying biology of EOPET is unclear. It is known that disrupted oxygen delivery and altered cellular differentiation are characteristics of preeclampsia placentas, and that this likely has an effect on the placental molecular profile. This thesis primarily investigates DNA methylation, a key component in regulating gene expression, in placentas and cellular states related to EOPET. Investigating placental cells exposed to hypoxia, we found 147 CpG sites in cytotrophoblast whose DNA methylation was significantly altered by exposure to hypoxia for 24 hours. Many of these sites overlapped with the 223 CpG sites that were altered between normoxic cytotrophoblast and syncitiotrophoblast, however the change was in the opposite direction (hypomethylated vs. hypermethylated), implying hypoxia can molecularly prevent differentiation in trophoblast cells. Expanding on these findings to look at DNA methylation in placental tissue from preeclampsia pregnancies, we found significant differences at 282 CpG sites. Several of these differences occurred in genes that have functional relevance for the development of EOPET. Many of the candidate genes also showed differential gene expression in preeclampsia placentas. To investigate the utility of these candidate CpGs as 1st trimester EOPET biomarkers, placentas with increased susceptibility to preeclampsia (trisomy 16) were investigated across gestational ages. There were many DNA methylation differences in 3rd trimester trisomy 16 placentas that were shared with chromosomally normal 3rd trimester EOPET placentas, suggesting a common molecular profile of preeclampsia prone placentas, regardless of etiology. Comparing 1st trimester trisomy 16 against 3rd trimester trisomy 16, we found 77 CpG sites differentially methylated in both conditions, and further found 3 changes in first trimester trisomy 16 shared with 3rd trimester EOPET. Overall, these studies have identified several molecular changes in EOPET and related conditions that provide insight into the biology of the disorder while also providing novel candidates to investigate further in a clinical setting.
View record
Each year, many pregnancies are associated with obstetrical complications such as maternal pre-eclampsia (PET) and fetal intrauterine growth restriction (IUGR). Poor placentation is thought to contribute to these complications, but specific causes are largely unknown. Mouse models suggest that epigenetic mechanisms, in particular genomic imprinting, that alter gene regulation may help regulate placental development and embryonic growth. The first goal of this thesis is to examine if epigenetic modifications (i.e. DNA methylation) and altered expression of imprinted genes in the human placenta are contributing factors to PET and IUGR. The second goal of this thesis is to identify imprinted loci that are useful in the diagnosis of placental pathologies that associated with abnormal imprinting, including triploidy, hydatidiform moles, and placental mesenchymal dysplasia. I found that DNA methylation at the imprinting control region 1 (ICR1) on chromosome 11p15.5 was significantly decreased in IUGR placentas (p 0.001), but not in those associated with pre-eclampsia. Methylation at ICR2 (KvDMR1) was not significantly altered in PET or IUGR. No significant changes in expression levels were observed in the genes controlled by these ICRs. There were no significant methylation changes observed in any candidate imprinted gene evaluated by the Illumina array. LINE-1 methylation, a marker of whole genome methylation, was also similar in all groups. The establishment of biomarkers that could be used to accurately identify those women at an increased risk for pre-eclampsia or IUGR would be a major step forward in antenatal care. All placental pathologies (triploidy, hydatidiform moles or placental mesenchymal dysplasia) were associated with altered ICR2 (KvDMR1) methylation. Pyrosequencing assays for SGCE, SNRPN, and MEST were also compared for their utility in diagnosing parental genomic imbalance in placental samples. SGCE showed the clearest separation between groups. The combined use of KvDMR1 and SGCE assays could provide a potentially valuable diagnostic tool in the rapid screening of methylation errors in placental disorders. These results also demonstrate the maintenance of imprinting status at these loci in the human placenta, even in the presence of abnormal pathology.
View record
Current Students & Alumni
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.
Membership Status
Location
Program Affiliations
Academic Unit(s)